Diagnosis of melanoma under concomitant natalizumab therapy by Vavricka, B M P et al.
Letter to the Editor 
 
 
 
Diagnosis of Melanoma Under Concomitant Natalizumab Therapy 
 
 
Bettina M. Prinz Vavricka MD
1,2
, Peter Baumberger MD
3
, Stefan Russmann MD
1
, Gerd A. Kullak-
Ublick MD
1 
 
 
1
Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Switzerland, 
2
Division of Dermatology, University Hospital Zurich, Switzerland 
3
Neurology, Private practice, Frauenfeld, Switzerland 
 
 
 
 
 
Funding sources: none 
 
Conflicts of interest: None declared     
 
 
 
Correspondence:  
Gerd A. Kullak-Ublick, MD 
Division of Clinical Pharmacology and Toxicology 
University Hospital  
Raemistrasse 100 
CH-8091 Zurich 
Switzerland 
Phone: +41 44 255 40 97 
Fax:    +41 44 255 4411 
e-mail: gerd.kullak@usz.ch  
To the Editor: We have read with great interest the short report on natalizumab and melanoma from 
Bergamaschi and Montomoli published recently in this journal.
1
 Natalizumab (Tysabri, Biogen Idec and 
Elan Pharmaceuticals) is a humanized monoclonal antibody against α4 integrins used in the treatment 
of multiple sclerosis and Crohn’s disease.
2
 Mullen et al reported on two cases of melanoma in patients 
with multiple sclerosis receiving natalizumab.
3
 Their letter was criticized since case reports in general 
show limited interpretability in establishing cause-and-effect relationships
3
 and since controlled clinical 
trials and postmarketing surveillance studies did not indicate an increased risk of melanoma in patients 
receiving natalizumab.
2
 However, melanoma is underreported to cancer registries as compared to 
other cancers due to its occurrence in the outpatient setting
5
 and therefore, postmarketing surveillance 
studies might also underestimate the true incidence of melanomas as side-effect of any drug therapy.   
We report here on a 41-year-old woman who had been treated with natalizumab (once per month i.v.) 
for 15 months for multiple sclerosis. The patient had no known history of melanoma but displayed 
many atypical moles for years that were regularly checked by a dermatologist. The family history was 
negative for melanomas and she did not expose herself to sunlight regularly. She noticed a rapidly 
growing mole on her upper arm. On evaluation it proved to be a superficial spreading melanoma in situ 
pTis (SSM-type) on the basis of a dysplastic nevus of a compound-type. The lesion was excised in 
total. Other moles were also removed but did not show any histological signs of melanoma. An eye 
examination with a special focus on the retina revealed no signs of ocular melanoma. The patient is 
now on regular follow-up with a dermatologist and showed no other transdifferentiation of the known 
nevi. She is still on natalizumab therapy.  
The occurrence of melanoma in our patient was in close temporal relation to the administration of 
natalizumab and an alteration in a long-standing nevus. It should be taken into account that anti- α4  -
integrin antibodies suppress the immune system by inducing apoptosis in lymph-node T cells in an in 
vitro model
6
 which could explain the potential of melanoma cells to spread. The already published 
case reports together with the present case report should raise the awareness of this possible side 
effect of developing melanoma under natalizumab therapy. Medical doctors using natalizumab should 
consider regular dermatological check-ups for their patients until further data are available.    
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